Anti-CD3/anti-B7-H4 bispecific T-cell engager therapy (AbCellera Biologics)

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameAnti-CD3/anti-B7-H4 bispecific T-cell engager therapy (AbCellera Biologics)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3Anti-V-set domain-containing T-cell activation inhibitor 1

TargetsT cell surface glycoprotein CD3V-set domain-containing T-cell activation inhibitor 1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAbCellera Biologics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAbCellera Biologics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A